Adial Pharmaceuticals (ADIL) Return on Equity (2022 - 2024)
Adial Pharmaceuticals' Return on Equity history spans 3 years, with the latest figure at 2.19% for Q3 2024.
- For Q3 2024, Return on Equity fell 196.0% year-over-year to 2.19%; the TTM value through Sep 2024 reached 2.19%, down 196.0%, while the annual FY2023 figure was 0.51%, N/A changed from the prior year.
- Return on Equity for Q3 2024 was 2.19% at Adial Pharmaceuticals, down from 1.73% in the prior quarter.
- Across five years, Return on Equity topped out at 0.58% in Q4 2023 and bottomed at 2.94% in Q1 2023.
- The 3-year median for Return on Equity is 1.65% (2023), against an average of 1.37%.
- The largest annual shift saw Return on Equity soared 270bps in 2023 before it tumbled -196bps in 2024.
- A 3-year view of Return on Equity shows it stood at 2.11% in 2022, then skyrocketed by 128bps to 0.58% in 2023, then plummeted by -475bps to 2.19% in 2024.
- Per Business Quant, the three most recent readings for ADIL's Return on Equity are 2.19% (Q3 2024), 1.73% (Q2 2024), and 0.77% (Q1 2024).